Mesothelioma Clinical Trial Finder: 7 Steps to Find and Enroll in Studies

More than 200 mesothelioma clinical trials are actively enrolling patients in the United States right now, including studies testing CAR-T cell therapy, next-generation immunotherapy combinations, novel chemotherapy agents, and tumor-treating electric fields—most of which are provided at no cost to participants. Finding the right trial requires knowing where to search, how to read eligibility criteria, and how to navigate the enrollment process without losing valuable treatment time.

What Are the Key Facts About Mesothelioma Clinical Trials?

• ClinicalTrials.gov, maintained by the U.S. National Library of Medicine, is the authoritative registry for all federally registered clinical trials including mesothelioma studies
• Most mesothelioma trials add experimental treatment on top of standard care rather than replacing it with a placebo, reducing the risk of receiving no active treatment
• The investigational drug or device in a clinical trial is typically provided at no cost to participants; routine care costs are usually covered by insurance
• Mesothelioma trials are available for all disease stages—early-stage, locally advanced, metastatic, and recurrent—as well as all cell types (epithelioid, sarcomatoid, biphasic)
• Major mesothelioma trial sites include MD Anderson Cancer Center, Memorial Sloan Kettering, Brigham and Women's Hospital, UCLA Health, and Moffitt Cancer Center
• Participation in a clinical trial does not prevent you from pursuing legal compensation through asbestos trust fund claims or lawsuits simultaneously
• You can withdraw from a clinical trial at any time without affecting your eligibility for standard treatment
• The NCI provides a free clinical trial matching service that filters available trials by your specific diagnosis, stage, and treatment history
• Phase II and Phase III trials typically offer the highest standard of care combined with experimental treatments with the most evidence behind them
• Informed consent is legally required before trial enrollment and must include full disclosure of known risks, benefits, and alternatives

Why Should Mesothelioma Patients Consider Clinical Trials?

Mesothelioma has a limited menu of standard treatments—surgery for eligible patients, chemotherapy with pemetrexed and platinum agents, and immunotherapy with nivolumab plus ipilimumab for unresectable disease. These options have improved median survival modestly over the past two decades, but mesothelioma remains one of the most treatment-resistant cancers in oncology.

Clinical trials represent the frontier of mesothelioma medicine. According to the Clinical Trials page at WikiMesothelioma, active mesothelioma research is testing arginine-depletion therapy (ADI-PEG20/ATOMIC-Meso trial), CAR-T cell approaches, tumor microenvironment modulation, and novel immunotherapy combinations that have shown early-phase promise. Patients who enroll in trials contribute to advances that will help future patients—while simultaneously gaining access to treatments their community oncologists may not be able to prescribe for years.

For mesothelioma specifically, trial participation may provide meaningful clinical benefit above standard care. The National Cancer Institute's clinical trials program has been instrumental in establishing immunotherapy as a standard second-line option—a direct result of trial evidence generated by mesothelioma patients in prior decades.

"With 20 years in the pharmaceutical industry before this work, I can tell you that the trials running right now for mesothelioma are the most promising we've seen. Patients who assume clinical trials are a last resort are leaving their best options on the table. Ideally you're identifying relevant trials at diagnosis, not after standard options have failed." — David Foster, Executive Director of Client Services, 18+ Years Mesothelioma Advocacy, Danziger & De Llano

What Are the 7 Steps to Find and Enroll in a Mesothelioma Trial?

Step 1: Gather Your Diagnostic Profile

Before searching any database, collect the key information that determines trial eligibility. You'll need: your confirmed mesothelioma type (pleural, peritoneal, pericardial, or tunica vaginalis), cell type (epithelioid, sarcomatoid, or biphasic), disease stage (I–IV for pleural, early/advanced for peritoneal), your ECOG performance status (your oncologist can provide this), a list of all prior treatments and their dates, and recent lab results showing kidney, liver, and bone marrow function.

This diagnostic profile is the input for every trial eligibility screening. Having it organized before you search saves multiple follow-up calls to your care team.

Step 2: Search ClinicalTrials.gov

Navigate to ClinicalTrials.gov mesothelioma search and filter for Recruiting status. You can further refine by phase (Phase II or III typically offer the most mature protocols), location (use your ZIP code to find trials within a reasonable travel distance), and intervention type (drug, device, procedure, behavioral).

Each trial record includes an NCT number (the unique identifier), the trial title and sponsor, the primary and secondary endpoints, detailed eligibility criteria (inclusion and exclusion), enrollment sites with contact information, and the estimated primary completion date. The NCI guide to reading a trial record explains how to interpret each field.

Step 3: Use the NCI Matching Service

ClinicalTrials.gov shows you all registered trials but doesn't filter by eligibility. The National Cancer Institute's trial matching service cross-references your diagnostic profile against each trial's specific criteria and returns only trials you could potentially qualify for. This service is free and requires no personal information beyond your diagnosis details.

Major cancer centers including MD Anderson, Memorial Sloan Kettering, and Brigham and Women's also maintain their own trial matching portals that are worth checking in addition to the NCI tool. The Mesothelioma Treatment Centers guide at WikiMesothelioma lists the major specialized centers and their contact resources for trial inquiries.

"The NCI matching tool is underused because patients don't know it exists. It's the difference between scrolling through 200 general results and getting 8 trials filtered to your exact diagnosis, stage, and treatment history. I recommend it to every newly diagnosed mesothelioma patient I work with." — David Foster, Executive Director of Client Services, Danziger & De Llano

Step 4: Review Eligibility Criteria Carefully

Every trial has inclusion criteria (requirements you must meet) and exclusion criteria (factors that disqualify you). Common exclusion criteria for mesothelioma immunotherapy trials include active autoimmune disease, prior organ transplantation, currently receiving systemic corticosteroids, and certain cardiac arrhythmias. Exclusion criteria are not arbitrary—they protect patient safety by excluding people whose underlying conditions could make trial treatment dangerous.

Don't self-disqualify based on eligibility criteria without consulting the trial team. Criteria are sometimes more flexible in practice than they appear on paper, and trial coordinators can clarify whether your specific situation is a true disqualifier or a judgment call.

Step 5: Contact Trial Sites and Pre-Screen

Each trial record lists at least one enrollment site with a contact email or phone number. Call or email the trial coordinator—not the principal investigator—with a brief summary of your diagnosis, stage, and prior treatment. The coordinator will conduct a brief phone pre-screen to determine whether a formal screening visit is warranted.

Come prepared with your diagnostic profile from Step 1. Most pre-screens take 20 to 30 minutes and can be completed by phone without travel. If the pre-screen is favorable, you'll be invited for an in-person screening visit that includes labs, imaging, and a consultation with the trial physician.

Step 6: Complete the Informed Consent Process

Before any trial-related procedures begin, you must sign an informed consent form (ICF) that describes the trial's purpose, procedures, potential risks, potential benefits, and your alternatives. The NIH's clinical research participant guidance confirms that informed consent be fully voluntary—you must be given adequate time to review the document, ask questions, and decide without pressure. Take the ICF home, read it carefully, and return with written questions.

Key questions to ask during informed consent: What is the trial's primary endpoint? What are the most commonly reported side effects in early-phase participants? What happens to my care if I need to withdraw? Will I be unblinded at the end of the trial?

Step 7: Coordinate with Your Existing Care Team

Inform your primary oncologist before enrolling in any trial. Trial participation typically requires treatment at the enrolling center, which may mean some appointments happen away from your usual cancer center. Most trial sites will co-manage your care with your local oncologist, sharing lab results and imaging. Establish a clear communication plan so your full medical team—including your mesothelioma attorneys managing compensation claims—is informed of any treatment changes that might affect your legal case timeline.

Our asbestos trust fund guide explains how clinical trial participation interacts with active legal claims. Trial enrollment does not disqualify you from filing or receiving trust fund compensation—but it's worth coordinating with your legal team to ensure medical documentation aligns with your claim requirements.

What Types of Mesothelioma Trials Are Currently Active?

The mesothelioma clinical trial landscape in 2026 spans several distinct therapeutic approaches, each targeting different aspects of the disease's biology.

Immunotherapy Combinations. Following ASCO's 2025 update establishing nivolumab plus ipilimumab as the standard of care for unresectable pleural mesothelioma, ongoing trials are testing third-agent additions, novel checkpoint inhibitors, and extended maintenance regimens. These trials typically enroll patients regardless of prior immunotherapy history and assess whether intensified combinations extend survival beyond current standards.

Arginine Depletion (ADI-PEG20). The ATOMIC-Meso Phase III trial tested ADI-PEG20, an enzyme that depletes arginine—an amino acid that mesothelioma cells cannot synthesize independently. Mesothelioma is one of the few tumor types that lacks the enzyme needed to make arginine, making this a tumor-selective approach. Phase III data expected in 2026 may change treatment algorithms for arginine-auxotrophic mesothelioma patients.

CAR-T Cell Therapy. Multiple Phase I/II trials are exploring chimeric antigen receptor T-cell therapies targeting mesothelin—a protein highly expressed on mesothelioma cell surfaces. Early results from MSK and NCI trials have shown disease control rates in refractory patients. These trials are currently available only at specialized academic centers.

Tumor Treating Fields (TTFields). The FDA-approved NovoTTF-100L system uses alternating electric fields to disrupt tumor cell division. Phase III data from the STELLAR trial established TTFields plus chemotherapy as a viable combination for unresectable pleural mesothelioma, and ongoing trials are exploring extended use and novel combinations.

Surgery + Neoadjuvant/Adjuvant Therapy. For surgically eligible patients, trials are exploring neoadjuvant immunotherapy before resection and adjuvant targeted therapy after surgery—similar to the approach showing success in other thoracic malignancies. These trials require pathologic staging and performance status evaluation before enrollment.

"The most important thing I can tell mesothelioma patients about clinical trials is this: participation requires no sacrifice of legal rights and usually no sacrifice of standard treatment. You get access to novel therapies, your care is monitored more closely than in standard treatment, and you contribute to a knowledge base that will help the next patient. There are very few situations where I'd advise against at least exploring trials." — David Foster, Executive Director of Client Services, Danziger & De Llano

What Questions Should You Ask Before Joining a Mesothelioma Trial?

The National Cancer Institute's list of trial questions provides a comprehensive framework, but these are the most critical for mesothelioma patients specifically:

About the trial design: Is this a randomized trial, and if so, what is the chance of receiving the experimental treatment versus standard care or placebo? What is the control arm receiving? Is cross-over to the experimental arm allowed if my disease progresses on the control arm?

About the treatment: What are the most commonly reported side effects, and how are they managed? How is the treatment administered (oral, IV, inhalation, device), and how often do I need to come to the cancer center? What will happen if I cannot continue treatment due to side effects?

About costs: What exactly is covered by the trial, and what will my insurance be billed for? Will the trial cover travel or lodging costs if the enrollment site is far from my home? Is there a patient assistance program if my insurance doesn't cover routine care costs?

About my legal case: Will participation in the trial affect the documentation of my asbestos exposure history or compensation claims? Your mesothelioma attorney should be informed of any trial enrollment to ensure medical records are properly preserved for legal proceedings. Our free mesothelioma attorney directory connects patients with lawyers who understand the intersection of clinical trial participation and ongoing compensation claims.

How Does Trial Participation Interact with Compensation Claims?

Mesothelioma patients enrolled in clinical trials retain full rights to pursue asbestos trust fund claims, personal injury lawsuits, and VA disability benefits simultaneously. Trial participation is not a legal waiver of compensation rights, nor does receiving trial treatment affect your ability to document asbestos exposure or prove causation.

Some nuances are worth discussing with your legal team: Trial medical records become part of your documented disease history and may be requested during claims processing. If your cancer responds dramatically to trial treatment, it could affect your legal timeline. The Mesothelioma Quick Facts reference at WikiMesothelioma notes that mesothelioma compensation averages $1 million to $2.4 million in settlements—regardless of treatment status. Your compensation rights do not diminish because you're pursuing cutting-edge treatment.

References

1. Clinical Trials — WikiMesothelioma
2. Mesothelioma Quick Facts — WikiMesothelioma
3. Mesothelioma Treatment Centers — WikiMesothelioma
4. ClinicalTrials.gov — Mesothelioma Studies
5. NCI Clinical Trials Information — National Cancer Institute
6. Mesothelioma — National Cancer Institute
7. Clinical Trials — MedlinePlus, U.S. National Library of Medicine
8. Questions to Ask About Clinical Trials — National Cancer Institute
9. Malignant Pleural Mesothelioma Guidelines — National Comprehensive Cancer Network
10. What Are Clinical Trials — National Cancer Institute
11. NIH Clinical Research Trials and You — National Institutes of Health
12. Participating in Cancer Clinical Trials — National Cancer Institute
13. How to Read a Clinical Trial Record — U.S. National Library of Medicine